Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
作者信息
Furst D E, Breedveld F C, Kalden J R, Smolen J S, Burmester G R, Dougados M, Emery P, Gibofsky A, Kavanaugh A F, Keystone E C, Klareskog L, Russell A S, van de Putte L B A, Weisman M H
机构信息
University of California, UCLA, Rheumatology, Division Los Angeles, USA.
出版信息
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii2-9. doi: 10.1136/ard.62.suppl_2.ii2.
Abstract
摘要
相似文献
1
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii2-9. doi: 10.1136/ard.62.suppl_2.ii2.
2
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
3
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.
4
Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
JAMA. 2003 Jun 25;289(24):3229-30. doi: 10.1001/jama.289.24.3229.
5
Rheumatoid arthritis and tuberculosis in the tumor necrosis factor inhibitors era: observations from Brazil.
J Clin Rheumatol. 2005 Dec;11(6):344-6. doi: 10.1097/01.rhu.0000191152.52925.31.
6
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
7
Drugs for rheumatoid arthritis.
Treat Guidel Med Lett. 2012 May;10(117):37-44; quiz 2 p following 44.
8
Management of rheumatoid arthritis.
Natl Med J India. 2004 May-Jun;17(3):143-51.
9
[Biopharmaceuticals in the treatment of rheumatoid arthritis].
Ugeskr Laeger. 2008 Jun 9;170(24):2108-10.
10
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272.
引用本文的文献
1
The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry.
Rheumatol Int. 2022 May;42(5):803-814. doi: 10.1007/s00296-021-05072-2. Epub 2022 Mar 26.
2
Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data.
Rheumatol Ther. 2020 Jun;7(2):311-325. doi: 10.1007/s40744-020-00198-4. Epub 2020 Feb 29.
3
Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results.
Biologics. 2018 Nov 27;12:171-182. doi: 10.2147/BTT.S187998. eCollection 2018.
4
Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
Patient Prefer Adherence. 2016 Feb 5;10:123-34. doi: 10.2147/PPA.S94396. eCollection 2016.
5
A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.
Chest. 2014 Mar 1;145(3):454-463. doi: 10.1378/chest.13-2408.
6
TNF-alpha antagonist therapy modify the tuberculin skin test response.
Rheumatol Int. 2011 Sep;31(9):1147-51. doi: 10.1007/s00296-010-1424-3. Epub 2010 Mar 27.
7
Higher C-reactive protein and soluble tumor necrosis factor receptor levels are associated with poor physical function and disability: a cross-sectional analysis of a cohort of late middle-aged African Americans.
J Gerontol A Biol Sci Med Sci. 2010 Mar;65(3):274-81. doi: 10.1093/gerona/glp148. Epub 2009 Oct 7.
8
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
BMC Musculoskelet Disord. 2008 Apr 17;9:52. doi: 10.1186/1471-2474-9-52.
9
The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.
Ann Rheum Dis. 2008 Aug;67(8):1139-44. doi: 10.1136/ard.2007.080440. Epub 2007 Nov 29.
10
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.
Rheumatol Int. 2007 Jul;27(9):793-806. doi: 10.1007/s00296-007-0357-y. Epub 2007 May 16.
本文引用的文献
1
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.
Ann Rheum Dis. 2003 Sep;62(9):817-24. doi: 10.1136/ard.62.9.817.
2
Case reports of heart failure after therapy with a tumor necrosis factor antagonist.
Ann Intern Med. 2003 May 20;138(10):807-11. doi: 10.7326/0003-4819-138-10-200305200-00008.
3
Successful treatment of resistant giant cell arteritis with etanercept.
Ann Rheum Dis. 2003 Apr;62(4):373-4. doi: 10.1136/ard.62.4.373.
4
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
N Engl J Med. 2003 Feb 13;348(7):601-8. doi: 10.1056/NEJMoa020888.
5
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
Arthritis Rheum. 2003 Feb;48(2):319-24. doi: 10.1002/art.10758.
6
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
Arthritis Rheum. 2003 Jan;48(1):218-26. doi: 10.1002/art.10710.
7
[Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].
Presse Med. 2002 Nov 23;31(39 Pt 1):1836-9.
8
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.
Int J Cardiol. 2002 Dec;86(2-3):123-30. doi: 10.1016/s0167-5273(02)00470-9.
9
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
Arthritis Rheum. 2002 Oct;46(10):2565-70. doi: 10.1002/art.10583.
10
Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents.
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii62-3. doi: 10.1136/ard.61.suppl_2.ii62.
Zotero 插件